CorMedix Backs FY26 Revenue Guidance of $325M-$345M
CRMD sits 25% above its 52-week low of $6.125.
Summary
CorMedix reaffirmed its fiscal 2026 revenue guidance of $325M-$345M, following Q2 revenue of $101.9M (up 157% YoY). The company narrowed its FY cash operating expense guidance to $145M-$155M and raised its FY adjusted EBITDA guidance to $125M-$140M. The revenue guidance implies a significant ramp in the second half, driven by MINOCIN for Injection and DefenCath. This follows a patent litigation win in June and a derivative lawsuit settlement last week. The reaffirmation removes uncertainty around the full-year outlook and supports the current valuation.
At the time of this announcement, CRMD was trading at $7.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557M. The 52-week trading range was $6.13 to $14.96. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.